The treatment of patients with low tumour burden and/or slow growing disease.
In the evaluation of the wide range of novel therapeutics which have been developed, investigators do not have to be tied to the current paradigm of demonstrating additive efficacy to first line combination therapy. The addition of new agents to FOLFOX regimens has proved a high hurdle at which many...
Hoofdauteur: | Maughan, T |
---|---|
Formaat: | Journal article |
Taal: | English |
Gepubliceerd in: |
2011
|
Gelijkaardige items
-
The response of fast-, medium- and slow-growing chickens to a low protein diet
door: Darina Chodová, et al.
Gepubliceerd in: (2021-03-01) -
Is visual radiological evaluation of liver tumour burden in patients with neuroendocrine tumours reproducible?
door: Magaly Zappa, et al.
Gepubliceerd in: (2017-02-01) -
STING signalling compensates for low tumour mutation burden to drive anti-tumour immunityResearch in context
door: Jiayi Tan, et al.
Gepubliceerd in: (2024-03-01) -
Slow growing of Stieltjes integrals of monotone functions
door: M. V. Zabolotskyj, et al.
Gepubliceerd in: (2013-01-01) -
Cassava residues in the diet of slow-growing broilers
door: Silvia Silva VIEIRA, et al.
Gepubliceerd in: (2022-09-01)